ZA201505602B - Composition comprising an encapsulated antagomir - Google Patents

Composition comprising an encapsulated antagomir

Info

Publication number
ZA201505602B
ZA201505602B ZA2015/05602A ZA201505602A ZA201505602B ZA 201505602 B ZA201505602 B ZA 201505602B ZA 2015/05602 A ZA2015/05602 A ZA 2015/05602A ZA 201505602 A ZA201505602 A ZA 201505602A ZA 201505602 B ZA201505602 B ZA 201505602B
Authority
ZA
South Africa
Prior art keywords
composition
encapsulated antagomir
antagomir
encapsulated
Prior art date
Application number
ZA2015/05602A
Other languages
English (en)
Inventor
David Garcia-Dorado Garcia Antonio
Barba Vert Ignasi
Rodriguez Sinovas Antonio
Bellera Gotarda Neus
Perez Amadeo
Ferret Eulalia
Asin Miguel-Angel
Original Assignee
Fundacio Hospital Univ Vall D'hebron - Institut De Recerca
Pierre Fabre Medicament S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall D'hebron - Institut De Recerca, Pierre Fabre Medicament S A S filed Critical Fundacio Hospital Univ Vall D'hebron - Institut De Recerca
Publication of ZA201505602B publication Critical patent/ZA201505602B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2015/05602A 2013-01-24 2015-08-04 Composition comprising an encapsulated antagomir ZA201505602B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
ZA201505602B true ZA201505602B (en) 2017-05-31

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/05602A ZA201505602B (en) 2013-01-24 2015-08-04 Composition comprising an encapsulated antagomir

Country Status (16)

Country Link
US (1) US20150352055A1 (cg-RX-API-DMAC7.html)
EP (2) EP2759595B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016506923A (cg-RX-API-DMAC7.html)
KR (1) KR20160018451A (cg-RX-API-DMAC7.html)
CN (1) CN105229151A (cg-RX-API-DMAC7.html)
AU (1) AU2014208419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015017650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898958A1 (cg-RX-API-DMAC7.html)
ES (2) ES2606636T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219753A1 (cg-RX-API-DMAC7.html)
HU (1) HUE032125T2 (cg-RX-API-DMAC7.html)
MX (1) MX2015009323A (cg-RX-API-DMAC7.html)
PL (1) PL2759595T3 (cg-RX-API-DMAC7.html)
RU (1) RU2668794C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014115103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505602B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
BR112017015618A2 (pt) 2015-01-20 2018-04-10 Miragen Therapeutics Inc inibidores de mir-92 e usos destes.
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575A4 (en) * 2019-03-14 2022-10-26 M. Technique Co., Ltd. Plga microparticles, sustained release formulation thereof and method for manufacturing same
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
MX2010003299A (es) * 2007-10-04 2010-04-14 Santaris Pharma As Oligonucleotidos muy cortos (micromirs).
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US9072765B2 (en) * 2009-05-20 2015-07-07 Board Of Regents, The University Of Texas System Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure

Also Published As

Publication number Publication date
PL2759595T3 (pl) 2017-09-29
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
BR112015017650A2 (pt) 2017-11-21
CA2898958A1 (en) 2014-07-31
ES2688160T3 (es) 2018-10-31
JP2016506923A (ja) 2016-03-07
KR20160018451A (ko) 2016-02-17
RU2668794C2 (ru) 2018-10-02
US20150352055A1 (en) 2015-12-10
EP2948551B1 (en) 2018-05-02
CN105229151A (zh) 2016-01-06
EP2948551A1 (en) 2015-12-02
RU2015134770A (ru) 2017-03-03
EP2759595B1 (en) 2016-09-14
WO2014115103A1 (en) 2014-07-31
ES2606636T3 (es) 2017-03-24
HK1219753A1 (zh) 2017-04-13
EP2759595A1 (en) 2014-07-30
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
PL3065569T4 (pl) Kompozycja
GB201304662D0 (en) Compositions
HUE044039T2 (hu) Biokatalitikus készítmény
GB201608461D0 (en) Compositions
ZA201505602B (en) Composition comprising an encapsulated antagomir
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201318489D0 (en) Composition
GB201319540D0 (en) Composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
SG10201801521QA (en) Anti-obesity composition
GB201322772D0 (en) Composition
GB201317196D0 (en) Composition
IL225985A0 (en) Preparation@cosmetic@mushkollal
GB201307622D0 (en) Composition
PL2767164T3 (pl) Nowe kompozycje
GB201320962D0 (en) Compositions
SG11201602134QA (en) Encapsulation
GB201420672D0 (en) Composition
GB201316082D0 (en) Chitosan composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition